⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IONS News
Ionis Pharmaceuticals, Inc. Common Stock
Ionis updates time for fourth quarter and full year 2025 financial results webcast
businesswire.com
IONS
U.S. Orphan Drug Market Report 2026: A $200 Billion Opportunity by 2031 - Indication, Company, Trial Phase, Marketed Status of 1400 Drugs, Drug Sales of 150 Drugs, Pricing and Dosage of 400 Drugs
globenewswire.com
BMY
GILD
JNJ
SNY
TAK
AMGN
AZN
LLY
MRK
PFE
REGN
VRTX
ABBV
ALNY
AMTX
BIIB
BMRN
CRSP
EXAS
INCY
IONS
JAZZ
NTLA
PTC
RGEN
XOM
Ionis to hold fourth quarter and full year 2025 financial results webcast
businesswire.com
IONS
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy
globenewswire.com
IONS
BIIB
Vect-Horus Enters a CNS-Focused Research Collaboration with OliX Pharmaceuticals
globenewswire.com
IONS
Next Generation Drug Conjugates Market Trends and Global Forecasts, 2025-2035 - Lutathera, Pluvicto, Givlaari, Oxlumo, Leqvio, and Amvuttra Represent Milestones in Advanced Treatment Solutions - ResearchAndMarkets.com
businesswire.com
NVS
ALNY
ARWR
GERN
IONS
Amyloidosis Therapeutic Market to Worth Over US$ 6.37 Billion by 2033 | Astute Analytica
globenewswire.com
PFE
ALNY
IONS
JNJ
TSE
GEHC
DAWNZERA™ (donidalorsen) approved in the European Union for hereditary angioedema (HAE)
businesswire.com
IONS
Diabetic Neuropathy Clinical Trial Pipeline Gains Momentum: 18+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
NVO
IONS
PFE
REGN
LXRX
VRTX
LLY
$15.5 Bn Next Generation Drug Conjugates Market Trends and Global Forecasts, 2035
globenewswire.com
ALNY
ARWR
GERN
IONS